{
    "clinical_study": {
        "@rank": "25132", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD."
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD."
            }
        ], 
        "brief_summary": {
            "textblock": "PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary\n      purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and\n      pharmacodynamics of single oral doses of PF-06678552 in healthy subjects."
        }, 
        "brief_title": "A Single Dose Study Of PF-06678552 In Healthy Subjects", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects of non childbearing potential.\n\n          -  Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight >50 kg\n\n          -  Low density lipoprotein cholesterol between 115 mg/dL and 190 mg/dL\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992614", 
            "org_study_id": "B7611001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.", 
                "intervention_name": "PF-06678552 or Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.", 
                "intervention_name": "PF-06678552 or Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.", 
                "intervention_name": "PF-06678552 or Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Single Ascending Dose", 
            "healthy subjects", 
            "Hypercholesterolemia", 
            "Hyperlipidemias", 
            "Dyslipidemias", 
            "Lipid Metabolism Disorders", 
            "Metabolic Diseases"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7611001&StudyName=A%20Single%20Dose%20Study%20Of%20PF-06678552%20In%20Healthy%20Subjects"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Fed And Fasted Administration Of Single Escalating Oral Doses In Healthy Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assessment of adverse events (AEs), clinical laboratory tests, vital signs (including blood pressure and pulse rate) and cardiac conduction intervals as assessed via 12-lead electrocardiogram (ECG).", 
            "safety_issue": "Yes", 
            "time_frame": "0 to 72 hours post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992614"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06678552", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "AUC (0 - infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - infinity)] for PF-06678552", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Maximum Observed Plasma Concentration (Cmax)", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) for for PF-06678552", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06678552", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Plasma Decay Half-Life (t1/2)", 
                "measure": "Plasma Decay Half-Life (t1/2) for PF-06678552", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F) for PF-06678552", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F) for PF-06678552", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06644927", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "AUC (0 - infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - infinity)] for PF-06644927", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Maximum Observed Plasma Concentration (Cmax)", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) for PF-06644927", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06644927", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Plasma Decay Half-Life (t1/2)", 
                "measure": "Plasma Decay Half-Life (t1/2) for PF-06644927", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose"
            }, 
            {
                "description": "Amount of drug excreted in the urine is a measure of the degree that the kidneys filter drug from the blood to the urine.", 
                "measure": "Amount of PF-06644927 excreted in the urine (Ae)", 
                "safety_issue": "No", 
                "time_frame": "0-4, 4-12, and 12-24 hours post dose"
            }, 
            {
                "description": "The percent of PF-06678552 dose excreted in the urine as PF-06644927 is calculated from the mass of dose excreted in the urine compared to the total dose of PF-06678552 and corrected for the relative weight of PF-06644927 to PF-06678552.", 
                "measure": "Percent of PF-06678552 dose excreted in the urine as PF-06644927 (Ae%)", 
                "safety_issue": "No", 
                "time_frame": "0-4, 4-12, and 12-24 hours post dose"
            }, 
            {
                "description": "Renal clearance is the measure of the rate of drug moving into the urine from blood", 
                "measure": "Renal Clearance (CLr) for PF-06644927", 
                "safety_issue": "No", 
                "time_frame": "0-4, 4-12, and 12-24 hours post dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}